MedTrace Logo

Activation of Brown Adipose Tissue Metabolism Using Mirabegron

NCT04823442 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-12-09

No results posted yet for this study

Summary

Could sympathomimetics and sympatholytics drugs safe for the management of Type 2 Diabetes (T2D)? Based on recent evidence, we propose that pharmacological stimulation of Beta-3 adrenergic receptor (ADBR3) at higher doses of Mirabegron may be required to elicit changes in glycemia, but should be combined with Beta-1 adrenergic receptor (ADRB1) antagonists to suppress the unwanted effects on the cardiovascular system.

Together, several results establish a previously unappreciated cross-talk between Gs-coupled ADRB1 and ADRB3 in adipose tissue for the control of glucose homeostasis. Moreover, these data suggest that antagonizing ADRB1 may be a good way to significantly lower the dose of ADRB3 agonist required for glucose control.

Therefore, we believe that there are therapeutic opportunities in targeting adrenergic receptors for the treatment of T2D at least in young/middle aged people.

Conditions

Interventions

DRUG

Mirabegron

Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)

DRUG

Bisoprolol Fumarate

a single dose of 10 mg (2 tablets of 5 mg)

Sponsors & Collaborators

  • Laval University

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Denis Blondin · Université de Sherbrooke

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2022-04-04
Completion
2022-04-04

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823442 on ClinicalTrials.gov